Manufacturing can make or break the future of cell and gene therapy. In this episode, Stuart sits down with two expert guests to share how smart design, automation, and closed systems are helping to lower costs, reduce complexity, and make therapies more accessible. From scaling strategies to operator-friendly technology, they reveal why manufacturing isn’t just a back-end process, but a critical part of therapy development from day one.
Guests:
- Professor Mark Lowdell, CSO InMune Bio Inc
- Luc Henry, Founder and CEO at Limula
The previous 4 episodes can be found on the listening platforms.
